Converge Technology Solutions Corp. (TSE:CTS – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is C$9.83.
Several equities analysts have commented on the company. Raymond James dropped their target price on Converge Technology Solutions from C$9.50 to C$8.50 in a research report on Friday, October 28th. Eight Capital dropped their target price on Converge Technology Solutions from C$11.00 to C$10.00 in a research report on Thursday. BMO Capital Markets dropped their target price on Converge Technology Solutions from C$9.00 to C$8.00 in a research report on Friday. Cormark dropped their target price on Converge Technology Solutions from C$10.00 to C$8.00 in a research report on Thursday. Finally, CIBC decreased their price target on Converge Technology Solutions from C$8.00 to C$7.00 and set a “neutral” rating for the company in a research note on Thursday.
Converge Technology Solutions Price Performance
Converge Technology Solutions stock opened at C$4.67 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.68 and a debt-to-equity ratio of 63.41. The company has a market capitalization of C$982.18 million and a PE ratio of 42.45. Converge Technology Solutions has a 12 month low of C$3.95 and a 12 month high of C$12.65. The stock has a 50-day moving average price of C$5.95 and a two-hundred day moving average price of C$6.16.
About Converge Technology Solutions
Converge Technology Solutions Corp. provides software-enabled IT and cloud solutions for corporate and government institutions in the United States and Canada. Its solutions approach delivers advanced analytics, application modernization, cloud, cybersecurity, digital infrastructure, and digital workplace offerings to clients across various industries.
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Converge Technology Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Converge Technology Solutions and related companies with MarketBeat.com's FREE daily email newsletter.